Johnson & Johnson (JNJ)

JNJ on New York Consolidated

93.77USD
1 Aug 2013
Price Change (% chg)

$0.27 (+0.29%)
Prev Close
$93.50
Open
$94.16
Day's High
$94.40
Day's Low
$93.71
Volume
11,061,909
Avg. Vol
9,849,629
52-wk High
$94.42
52-wk Low
$66.85

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.58
Market Cap (Mil.): $262,630.91
Shares Outstanding (Mil.): 2,808.89
Dividend: 0.66
Yield (%): 2.82

Financials

  JNJ Industry Sector
P/E (TTM): 20.78 37.93 37.76
EPS (TTM): 4.50 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

Energizer loses two battery accounts, will buy a J&J unit

- Energizer Holdings Inc said on Wednesday that two U.S. retailers planned to stop selling its batteries, adding pressure to its sagging sales.

31 Jul 2013

FDA limits use of J&J's Nizoral antifungal drug on safety concerns

- The Food and Drug Administration said it would limit the use of Johnson & Johnson's antifungal medicine, Nizoral tablets, warning that it may cause severe liver injuries and adrenal gland problems, and lead to harmful drug interactions.

26 Jul 2013

FDA limits use of J&J's Nizoral antifungal drug on safety concerns

July 26 - The U.S. Food and Drug Administration said it would limit the use of Johnson & Johnson's antifungal medicine, Nizoral tablets, warning that it may cause severe liver injuries and adrenal gland problems, and lead to harmful drug interactions.

26 Jul 2013

S&P retreats after eight days of gains as Coca-Cola drags

NEW YORK - The S&P 500 snapped its eight-day winning streak on Tuesday after disappointing sales from Coca-Cola, while investors turned cautious on the day before the Federal Reserve chairman's congressional testimony. | Video

16 Jul 2013

J&J results beat forecasts; Elan share sale helps

- Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings on strong demand for its prescription drugs and medical devices, but a big gain from the sale of a stake in Irish drugmaker Elan Corp skewed the results.

16 Jul 2013

UPDATE 3-J&J results beat forecasts; Elan share sale helps

July 16 - Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings on strong demand for its prescription drugs and medical devices, but a big gain from the sale of a stake in Irish drugmaker Elan Corp skewed the results.

16 Jul 2013

CORRECTED-UPDATE 1-J&J results beat expectations, as drugs, devices deliver

(Corrects third paragraph to show Elan gain is not a special item)

16 Jul 2013

J&J results beat expectations, as drugs, devices deliver

July 16 - Johnson & Johnson reported higher-than-expected second-quarter earnings as strong sales of prescription drugs and medical devices more than offset anemic growth of its consumer products.

16 Jul 2013

J&J in $1 billion deal to bolster prostate-cancer focus

- Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.

17 Jun 2013

UPDATE 2-J&J in $1 bln deal to bolster prostate-cancer focus

By Ransdell Pierson June 17 - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand. J&J on Monday said Aragon's lead product, called ARN-509, has potential to help patients whose prostate cancer has not yet spread to other parts of the body, as well as patient

17 Jun 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$483.00
Provider: Stock Traders Daily
$495.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks